You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Taiwan-based Personal Genomics, which is developing a new single-molecule sequencing platform, has previously sued PacBio for patent infringement in the US.
10x asked the US District Court for the Northern District of California to dismiss a suit, while another district court judge denied a 10x motion to dismiss.
Prosecutors have added a twelfth fraud charge against former Theranos CEO Elizabeth Holmes, according to the Mercury News.
According to Retraction Watch, a US federal judge has ruled against Ohio State University professor Carlo Croce in a defamation case he brought.
Illumina had sought to exclude the Harmony test from the US Market, while Ariosa had sought to overturn the jury verdict with a post-trial maneuver.
Illumina had argued that Complete Genomics' patent covering two-color sequencing-by-synthesis chemistry was obvious, but the US PTAB disagreed.
According to CNBC, the criminal trial of Theranos founder Elizabeth Holmes has been delayed due to the coronavirus pandemic.
The plaintiffs allege that TAI's heart transplant rejection test MyTAIHeart infringes on their patent for the non-invasive diagnosis of graft rejection.
The Delaware jury said Oxford Nanopore had infringed three patents, but also found that they were invalid, mostly because they were not enabled.
The US Court of Appeals for the Federal Circuit sent the case, which had been thrown out in December 2018, back to the trial court.
Nature News reports that genomics is being applied to trace and try to prevent additional COVID-19 waves.
Rady's Children Hospital and San Diego County are teaming up to test pediatric patients and their families for COVID-19 to gauge the spread of the virus locally, according to the San Diego Union-Tribune.
Wildlife managers aim to boost the genetic diversity of Mexican gray wolves by placing captive-born foster pups into packs with similarly aged wild pups, the Mercury News reports.
In Science this week: Genetic Probability tool identifies likely diagnoses in 45 percent of inflammatory arthritis cases, and more.